TherapeuticaRy, enzymology offers a means of treatment in tumors, although certainly insufficiently investigated to date. Paul (I 9 Warburg, Posener and Negelein (1924) , Warburg (1956) and as reiterated by Weinhouse (1960) presented his famous concept on the prevalence of glycolysis and possibly, impaired respiration in certain tumors; Greenstein (1956) stated in the second famous concept his hypothesis of near uniformity of enzyme activities in a variety of transplanted tumors; Potter (1956 Potter ( , 1957 Potter ( , 1958 introduced the third famous concept of cancer metabolism called the " deletion hypothesis " which postulated (Bergel, 1961) that during the development towards the malignant state and after the cell has lost certain essential constituents, the presence of which, under normal conditions, exerts a vital influence on the regulation of growth and cell division; and such men as Berenblum (1956) , Bodansky (1956 Bodansky ( 1958 Bodansky ( , 1959 , Wroblewski (1958b Wroblewski ( , 1959b Gutman (1959) , DesnueRe (1961) , Bergel (1956 Bergel ( , 1960 Bergel ( , 1961 and numerous others have heavily contributed to cancer enzymology. King in 1959 has given an excellent history of common enzymes and the ideas concerning them in relation to physiologic processes, pointing out the importance of enzymes in pathologic processes and the great usefulness of their determination in body fluids as relates to diagnosis, prognosis and assessment of therapy. This review will be an attempt to survey the field of cancer enzymes; to assign an organized classification to the enzymes involved in oncology ; to present various advances made ; to discuss existing concepts, some methodology and trends ; to point out lesser known areas of current research ; and, to form a basis for harnessing the field of tumor enzymology wbich seems increasingly in a state of flux.
NOMENCLATURE, TERMINOLOGY AND CLASSIFICATION
The field of enzymology strictly defined, concerns the chemistry and mechanism of enzyme-catalyzed reactions, as weH as the chemistry of the enzymes themselves (Colowick and Kaplan, 1955) . As biocatalysts, the enzymes carry the advantage that they can be assayed more easily than other cellular constituents due to their function and by necessity, through tbis, include substrates and products of their catalytic activities (Bergel, 1961) . Bodansky (1959) called enzymes protein catalysts and reported in detail on mechanisms that may be important for diagnostic appheation of enzymes in medicine. He also reported on many biological aspects of enzyme activity, such as formation of enzymes in the organism ; distribution of enzymes among the various intracellular structures, as nucleus, mitochondria, microsomes and the supernatant fraction rich in glycolvtic enzymes remaining after the centrifugation of these particulate structures and, the localization of certain groups of enzymes indicating the association of metabolic function with intra-cellular structure. Ruch and Fulton (1960) defined the holoenzymes as composites of a dialyzable portion (coenzymes) when a prosthetic group may be separated from the enzyme by dialysis, and a non-dialyzable protein part (apoenzymes). Bergel (1961) has elaborated on these families of enzymes which, together with their coenzymes, metal activators, metabolic pathways and cycles, differ in their activity and pattern in some tumors from those present in embryonic proliferating and resting normal tissues.
The word, enzyme, itself was introduced in 1876 by Willy Kiihne (cited by Wain, 1958) (King and Campbell, 1961 ; Freeman, 1961 ;  Thompson, 1962 (Long, King and Sperry, 1961 ; Fishman, 1960a, b) . Currently many investigators have reported on the structural differences among LDH fractions, for example, Hill (1958 Hill ( , 1961 , Plageman et al. (1960) , Wroblewski (1958a Wroblewski ( , 1959b , Nisselbaum and Bodanskv (1961a, b) , Dixon and Webb (1958) , VeseR and Bearii (1958) (Sayre and Hill, 1957 ;  Hill) Wieme, 1959a; Starkweather et al., 1961 ; Vesell and Bearn, 1961 ; W6rner and Martin, 1961 ; Latner and SkiRen, 1961; Dioguardi et al., 1961b; Laursen, 1962) . These findings may indicate the specific tissue from which they derive and such data would enable the chnical chemist in the future to not merely report an LDH activity in the patient but supply the cancer diagnostician with the cellular source from which originating. This kind of diagnostic potential becomes obvious since LDH is elevated in most cancer as well as many other diseases and consequently is not an adequate screening test per se.
LDH in abnormal levels in body fluids has been reported in relation to leukemia (Hill and Levi, 1954 ; Bierman et al., 1957 ; Bodanski, 1961) , gastric cancer (Schenker, 1959) , lymphomas (Bierman et al., 1957 ; , central nervous system involvement by metastatic carcinoma and in most malignant tumors (Wroblewski and LaDue, 1955; White, 1958a, b; Van Rymenant and Tagnon, 1959a; Fylling, 1961) . Wroblewski (1958a) Tryptophan Peroxidase, TPO, has been studied rather widely by enzymologists and chemists interested in tryptophan metabolism (Posnanskaya, 1958; Douglas, 1959, unpublished results; Chan et al., 1960 ; Long et al., 1961 ; Bergel, 1961) . TPO of the liver is considered an adaptive enzyme controlling tryptophan metabofism and theoretically with such a relationship to an essential amino acid, an understanding of its role in disease is necessary. Evidence presented by Posnanskaya (1958) (Bergel, 1961) . Bover and Candela (1961) (1956, 1958, 1959) , De Lamirande et al. (1958) , Dalgliesh (1952) , Efliot and Wilkinson (1961) , Frei et al. (1961) , , GrbnvaR (1961) , Hayaishi (1962) , Hfll et al. (1956) , Hill and Jordan (1957) , Holmberg and Laurell (1951) , Hsieh et al. (1955 Hsieh et al. ( , 1956 ), Hsieh and Blumenthal (1956) , Humoller et al. (1958) , Jagt and Larsen (1960), King (1957) , Kirkeby and Prydz (1959) , Laursen (1959 Laursen ( , 1962 , Meister (1950) , Plummer and Wilkinson (1962) , Rapp and BeR (1961), Riley and Wroblewski (1960) , Robert and Van Rymenant (1961) , Singer and Kearney (1957) , Stekol (1959) , Vetter (1961) , Wieme (1959b) , Zucker and BoreUi (1958) , .
TRANSFERASES
In this category may be hsted many enzymes that have been mentioned in relation to cancer, but always as non-specific enzymes for neoplastic disease and usuaRy affected by many other disease conditions.
Glutamic Oxaloacetic Transaminase (Aspartate Aminotransferase), GO-T, and Glutamic Pyruvic Transaminase (Alanine Aminotransferase), GP-T, are most pronunent in this class. Elevations in GO-T and GP-T activity levels have been associated with a multiplicity of diseases (Wroblewski, 1959a) , but may have diagnostic importance when carefully correlated with chnical facts. Examples are metastatic and primary hepatic carcinoma which become reflections of the enzyme changes at the intraceRudar tissues.
GO-T and GP-T serum levels are always increased in diseases involving destruction of liver cells. Transamination itself, the reaction between an alphaamino acid and an alpha-keto acid tbxough which the amino group is transferred from the former to the latter, has a tendency to relate tumors to protein biosynthesis and degradation if the concept that apoenzymes are products of certain polypeptides which are products of ribonucleic acid and nucleotides. Extensive biochemical studies of enzymatic transamination have overshadowed chnical imphcations of GO-T and GP-T activity in humans, yet these transaminases are readily measurable by comparatively simple techniques (Karman et al., 1955 ;  Henley and Pollard, 1955 ; Laursen and Espersen, 1.959 ; Laursen and FromHansen, 1958; Wroblewski, 1958b Wroblewski, , 1959a Aspen and Meister, 1958) . Transaminases appear to be measures of cefl damage rather than cen function and can be regarded as normal intracellular enzymes. Eastham (1960) stated that when patients have infiltration of the liver, cases of carcinoma, leukemia and lymphoma may show an increased activity.
In more recent years, other transferases have received much attention but so far not achieved major significance. Phosphoglucomutase, PGM, the glycolytic enzyme (Colowick and Kaplan, 1955) that converts glucose-l-phosphate to glucose-6-phosphate and requires glucose-1, 6-diphosphate as cofactor (Fisbman, 1960b) , a reversible conversion, has been reported as elevated in patients with metastatic disease (Bodansky, 1961) and bears a consistent abnormal pattern in mosteancerconditions. Bodansky(1957a) hasdevelopedamethodfordetermina-tion of PGM activity in serum and has applied it successfully to the chnical investigation of cancer of the breast. PGM occurs in aR cells (Fishman, 1960b ; Long et al., 1961) (Bodansky, 1961) , because much attention has been directed toward the investigation of PK in blood, it is noteworthy to say that this enzyme remains insignificantly altered in advanced cancer and widespread metastases.
Ornithine Carbamoyltransferase, OCT, an enzyme incompletely studied, but theoreticaRy looming as a diagnostic potential of value in neoplastic disease of liver and other organs, remains to be developed. Reichard (1957) Allard, 1959 ; Fishman, 1960b Long et al., 1961 Josefsson and Lagerstedt., 1962) and it has even been reported in recent literature that there exist several isoenzymes of RN which differ in their pH optima, their tissue origin or their nucleotide end-products (Bergel, 1961) .
Galactose-l-Phosphate Uridylyltransferase, an enzyme possibly under genetic control has been proposed as indirectl having a role in the mechanisms of cancer enzymology (Strauss, 1960) .
Some relationship has been suggested between tumor development and enzymes of the fatty acid metabolism but so far is too purely chemical to interest becologists (Stern et al., 1956a, b ; Robinson et al., 1957 Gomori, 1941; Abul-Fadl and King, 1948; Herbert, 1946; Woodard, 1952 Woodard, , 1959 PoweR and Smith, 1954; Bonner, Homburger and Fishman, 1954; Bodansky, 1954a Bodansky, , 1959 Bodansky, , 1961 Nylander. 1955; Mather, Richmond and Sprunt, 1956; Fishman and Davidson, 1957; Fishman, 1960a; Pearse, 1960; Benson, 1957; Bergel, 1961 ; A-nnino, 1960 -Zucker and Borelli, 1959; Long, King and Sperry, 1961 ; Meijer, 1962) . It is redundant to say this enzyme is extremely important in the diagnosis of metastasizing carcinoma of the prostate. Gutman and Gutman (1940) having reported from their data that increases to several hundredfold over the normal range for ACP activity were noticeable in subjects with prostatic carcinoma especially when the tumor extended outside the gland. ACP Gray (1959) reported that the plasma acid phosphatase derived from the prostate was inactivated by treatment with alcohol and this behavior useful in deciding whether an increased ACP activity level was due to prostatic carcinoma or to liberation of the ACP from red blood ceRs by hemolysis. Woodard (1959) (Harper, 1958) .
Much work and study have gone into the relationship of ACP to mammary cancer (Reynolds, et al., 1956 ; Lemon et al., 1958 ; King, 1959 ; Eastham, 1960 ; Fishman, 1960b) (Franseen and McLean, 1935 ; Gutman et al., 1936 ; Bruns and Jacob, 1954 ; Bodansky, 1956 Bodansky, , 1959  Schlamowitz and Bodansky, 1959; Gutman, 1959; Gray, 1959; Fishman, 1960a; Fischer and Siebert, 1961 ; Barnes and Cope, 1961) (Myers and Bodansky, 1957) and such has been also described by Griboff et al. (1954) Much speculatioii has centered around another phosphatase (Long et al., 1961) , 5-Nucleotidase, 5NT, which is optimally active at an alkaline pH and has ai-i alteratioii in many disease states (Bergel, 1961 ; Bodansky, 1961 ; Young, 1958 ;  Van Rymenant and Tagnon, 1959b). Dixon (Fishman, 1960b) . Thorough assay methods have been developed (Colowick and Kaplan, 1955 ; Fishman et al., 1948 ; Fishman et al., 1947) and histochemical procedures (Seligman, Nachlas, Manheimer, Friedman and Wolf, 1949) have demonstrated both animal and human tumors rich in this enzyme. It has been reported that the buffy coat of blood has high beta-glucuronidase activity (Fishman, 1960a) (Homburger and Fishman, 1956) . Elevations in cases of cancer of the breast are common (Cohen and Huseby, 195 la, b ; Fishman, 1960b ) -Fishman et al., 1954 . Much research has been performed and wiR be continued towards understanding this hydrolase (Fishman, 1949; Fishman and Anlyan, 1947 ; Fishman et al., 1959 Fishman and Bigelow, 1950 ; Homburger, 1960 ; Fishman and IvEtchell, 1959 Bodansky, 1961 ; Boyland et al., 1957 ; Rauramo, 1959a, b Bodansky, 1959 ; Stekol, 1958 ; Straub et al., 1957) , Glucose-6-Phosphatase (Weber '1959 ; Weber and Cantero, 1960 ; Kit, 1960) ,Arginase (ForsellandPalva,1961; FriedmanandBecker,1955; Pravdeena, 1957 ; Roberts, 1948) , Plasmin or Fibrinolysin (Long et al., 1961 ; Astrup, 1956) , Elastase (Lewis et al., 1956) , Chymotrypsin (Lundh, 1957 ; Billow et al., 1960 ; Brandborg et al., 1961) , Trypsin (Lundh, 1957 ; Astrup and Albrechtsen, 1957 ; Astrup and Sterndorff, 1955 ; Nardi and Lees, 1958) , Pepsin or Uropepsin (Gray et al., 1955 ; Jorgensen, 1954; Bock, 1954; Christensen, 1957a) , Deoxyribonuclease (Kowlessar et al., 1953 ; Brody, 1958 ; Brody and Balis, 1958) , Leucine Aminopeptidase (Dioguardi et al., 1961a ; Goldberg and Rutenburg, 1958) , Cholinesterase (Winkelman, 1961 ; Gal and Roth, 1957 ; Torp, 1956 ; Stovner, 1955 ; Sabine, 1951 ; Augustinsson, 1955) , Esterases (Green and Jenkinson, 1934), Cathepsins (Libenson and Jena, 1957) , and the Lipases (Cohn and Kaplan, 1960 ; Borgstr6m, 1957 ; Bergel, 1961 ; Best and Taylor, 1961) .
LYASES, ISOMERASES AND LIGASES
Relatively few lyases bear significance to date. Most noteworthy are aldolase, hyaluronidase, carbonic anhydrase, tryptophan synthase, hydroxytryptophan decarboxylase and possibly ketotetrosealdolase. The latter enzyme has been confused biochemically with aldolase (Wolf, Forster and Leuthardt, 1957) and is only negatively important in that it is consistently absent from serum in instances of liver metastases and normal serum, although appearing in serum of patients with viral hepatitis and other diseases. Hydroxytryptophan Decarboxylase has been examined by many protein and enzyme researchers (Cantero, 1955 ; Douglas, 1959, (Dux, Guerin and LaCour, 1948) nor from other correlations speculated upon (Truedsson, 1951 ; Bolio-Cicero et al., 1961 ; Gaines, 1960 ; Winslow and Taylor, 1960 ; Ekman et al., 1953 ; Faber and Schmith, 1950a, b ; Winslow and Enzinger, 1960) . Aldolase is a non-specific enzyme, elevated in most cancer conditions, but also in many other diseases. Baker and Govan (1953) (White, 1958b) . Some new lyases are insufficiently studied to report (Briiggemann et al., 1962 ; Briiggemann and Waldschmidt, 1962 Robert, 1961) .
Phosphohexose Isomerase (Glucosephosphate Isomerase), GPI, has been studied extensively by Bodansky (1954b, c, 1955, 1956 ) and shown to be raised in patients with metastatic cancer of breast or prostate and even more interesting, shown to have an " isomerase-mutase activity ratio " (Bodansky, 1957b) in serum, this proposed as an index of metastatic growth in the skeleton and/or liver within certain limitations. The ratio aforementioned was the result of Bodansky's comparison studies with serum phosphoglucomutase (1957a) and GPI (1957b) in metastatic cancer. An impressive degree of correlation was reported (Bodansky, 1954c) to exist between increases in serum GPI activity and growth of metastatic tumor in bone, as judged clinicaRy, and by biochemical methods, particularly by the urinary calcium excretion. Bodansky has demonstrated that such GPI activity can provide a useful index to growth or regression of tumor. Decreases toward normal GPI levels were associated with evidence of tumor regression whereas marked and sustained elevations very often preceded widespread metastases and death. but increases in GPI activity after a sequence of repeatedly normal levels was frequently the first herald of renewed growth of tumor. Strangely, much of the enthusiasm surrounding this enzyme has subsided in the past few years.
Israels and Delory (1956) have reported GPI significant in leukemia and, according to Van Rymenant and Tagnon (1959a) , the GPI activity of red blood cells is 160 times greater than that of plasma; however, in many types of hemolytic diseases, the GPI activity of plasma was low and contrasting with a high level of LDH activity, thus creating an increased ratio of LDH to GPI which might be indicative of the existence of a hemolvtic process in the blood of the patient (Blanchaer et al., 1958).
Myers and Bodansky (1957) reported a study of a patient with metastatic cancer of the breast in which two parameters of tumor activity, serum GPI and urinary-calcium, were determined over a nine-month period. They obtained high enzyme activity which possibly reflected active soft tissue disease in the liver although there was no biopsy proof of liver metastases.
White (1958b) (1958, 1962, 1962a, 1962b) (1956, 1961) , Vetter and Griesche (1961) , Vetter (1961) , Morton (1958) and many more are reviewed, it then becomes a postulate that human and animal enzyme activities in the body are altered in cancer. Specific tumors have produced certain enzymes ; as osteogenic sarcoma has produced ALP, or specific organs have secreted, when they are the site of cancer, certain enzymes as carcinoma of the prostate has secreted ACP, or general or localized reactions accompanyiiig certain cancers have produced LDH which correlated with the state and severity of leukemia (Homburger, 1960; Bierman et al., 1955) . The level of activity of beta-glucuronidase in the vaginal fluid is increased in nearlv every case of cancer of the cervix (Fishman et al., 1954 ; Kasdon et al., 1953) . The level of activity of uropepsin in benign gastric ulcer is high but in 80 per ceiit of gastric cancers is low (Gray et al., 1955) . The presence of tumor and distribution of enzymes are related.
The other factors, chemical and physiological and biophysical, are concisely stated in textbooks, reference books and various periodicals (Fenton, 1960 ; Ruch and Fulton, 1960; Long et al., 1961 ; Wolfson et al., 1.958; Wroblewski, 1959a; Robins, 1957 ; Endahl and Kochakian, 1957 ; Plummer and Wilkinson, 1962; Mason, 1958; Norberg, 1961 ;  Mendelsohn and Bodansky, 1952; Fishman and Davidson, 1957) (Colowick and Kaplan, 1955, 1962 ; Glick, 1959 Powell and Smith, 1954 ; Thiers and Vallee, 1958 ; Fraenkel-Conrat, 1957 Schmith and Faber, 1950; Tammelin, 1953 , Udenfriend et al., 1958 Cohn and Kaplan, 1960 ; Christensen, 1957a Christensen, ' 1957b Dawson et al., 1959; Dean and Woodard, 1947 ; Desnuelle, 1961) (Boyland and Watson, 1956 ; Boyland et al., 1957; Boyland, 1958) with tryptophan metabolites, and many recent reports pointed out by Berenblum (1956) and Bergel (1956 Bergel ( , 1960 Bergel ( , 1961 (1962) , which demonstrated that certain enzyme assays will benefit the following of clinical course in chemotherapy, as in 5-Fluorocil treatment, in which they found significance in enzymes of the uracil pathway during development of resistance. Cohen and Huseby (1951a, b) have noted estrogen therapy caused a marked rise in the beta-glucuronidase activity in the sera of patients being treated for mammary cancer with maximum values twice as high as the pre-therapy level. Farber (1955) and Bergel (1960 Bergel ( , 1961 stated that when there was an indicated permanent insufficiency of enzymes, or their co-factors could be given restitution or replacement for normal status, t11V need was to provide a holo-, apo-, coenzyme or model system with a specific enzymic activity.
Streptokinase or plasminokinase (Dixon and Webb, 1958) , the activator that converts plasminogen of blood plasma (Long et al., 1961) , an enzyme precursor, into a proteolytic hydrolase, called plasmin causin-a Ivsis of fibrin and liquifaction of any fibrinous exudate, has been employed therapeutically in man to disperse such exudates (Bridgwater and Necheles, 1957 ; Fletcher, 1954 (Astrup, 1956; Astrup and Sterndorff, 1955; Astrup and Albrechtsen, 1957) , Christensen (1957b) , Bridgwater and Necheles (1957) and Tillett et al. (Tillett and Garner, 1933 ;  Tillett, Johnson and McCarty, 1955) . Deoxyribonuclease of bacterial origin has also been employed clinicaRy in the treatment of purulent exudates (Bergel, 1961 ;  TiRett, Johnson and McCarty, 1955) . Chymotrypsint, a mixture of pancreatic enzymes (Cigarroa, 1960) , was employed to minimize the edema that followed radical mastectomy and neck dissection for malignant tumor. (1957, 1958) ; the clinical laboratory methodology of Seligson (1961) , Natelson (1961) and Annino (1960) ; the electron microscope applications of Fisher and Fisher (1961) ; the physical chemistry of Endahl and Kochakian (1957) Reid (1962) , Kizer (1962) , Kizer and Chan (1961) , Knox (1960) Grace and Lehoczky (1959) ; and more generahzed references, as the effect of physical stress on enzymes reported by Halonen and Konttinen (1962) , patterns and forms of enzymes reported by Markert and Mbller (1959) , employment of computer analysis as a new diagnostic tool reported by Mason et al. (1961) , discovery of a new " enzyme " reported by Murray (1961) , speculation on a probable peptidase reported by Pearse and Pepler (1957) Bodansky (1959) reported that some enzymes in the serum, such as alkaline phosphatase or transaminases, are mixtures of enzymes derived from several tissues.
Cryogenics and cryohomogenation offer a new tool for the understanding of multi-enzyme systems and metabolic pathways and provide a new foundation for the preparation and study of isolated enzyme systems (Klinkhamer and Eichel, 1962 There is some trend toward applying more profoundly chemotherapeutic efforts on the basis of enzymatic lesions revealed (Bergel, 1961 ; Weber and Cantero, 1960) (Weber, 1961 (Colowick and Kaplan, 1962) .
No statement has been made so far in regard to laboratory studies as proof for a given factor to produce cancer in man (Wynder, 1961) 
